OBJECTIVE: Cytotoxic T lymphocyte antigen-4 (CTLA4) gene polymorphism has been associated with human autoimmune diseases, but discordant data are available on its association with autoimmune Addison's disease (AAD). We tested the human leukocyte antigen (HLA)-independent association of CTLA4+49 (A/G) (Ala 17) and/or CTLA4 CT60 (A/G) polymorphism with AAD. DESIGN: DNA samples from 180 AAD patients and 394 healthy control subjects from continental Italy were analyzed, and association statistical analyses and meta-analysis of published studies were performed. Methods TaqMan minor groove binder chemistry assays and PCR fragment length polymorphism assays were used. RESULTS: Frequency of allele G of CTLA4+49 was significantly increased among AAD patients (40% alleles) than among healthy controls (27% alleles; P<0.0001). CTLA4 CT60 polymorphism was associated with AAD only in the heterozygous A/G individuals. The frequency of +49 AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a co-dominant (P<0.0001) and G dominant model (P<0.0001). CTLA4+49 allele G was significantly associated with disease risk in both patients with isolated AAD and in patients with autoimmune polyendocrine syndrome. Multivariate logistic regression analysis showed that CTLA4+49 allele G was positively associated with AAD (P<0.0001, odds ratio (OR)=2.43, 95% confidence interval=1.54-3.86) also after correction for DRB1*03-DQA1*0501-DQB1*0201, DRB1*04-DQA1*0301-DQB1*0302, and sex. Meta-analysis of five studies revealed a significant association of CTLA4+49 allele G with AAD (P<0.0001) with an overall OR of 1.48 (1.28-1.71). CONCLUSIONS: The CTLA4+49 polymorphism is strongly associated with genetic risk for AAD, independently from the well-known association with HLA class II genes.
OBJECTIVE:Cytotoxic T lymphocyte antigen-4 (CTLA4) gene polymorphism has been associated with humanautoimmune diseases, but discordant data are available on its association with autoimmune Addison's disease (AAD). We tested the human leukocyte antigen (HLA)-independent association of CTLA4+49 (A/G) (Ala 17) and/or CTLA4CT60 (A/G) polymorphism with AAD. DESIGN: DNA samples from 180 AAD patients and 394 healthy control subjects from continental Italy were analyzed, and association statistical analyses and meta-analysis of published studies were performed. Methods TaqMan minor groove binder chemistry assays and PCR fragment length polymorphism assays were used. RESULTS: Frequency of allele G of CTLA4+49 was significantly increased among AAD patients (40% alleles) than among healthy controls (27% alleles; P<0.0001). CTLA4CT60 polymorphism was associated with AAD only in the heterozygous A/G individuals. The frequency of +49 AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a co-dominant (P<0.0001) and G dominant model (P<0.0001). CTLA4+49 allele G was significantly associated with disease risk in both patients with isolated AAD and in patients with autoimmune polyendocrine syndrome. Multivariate logistic regression analysis showed that CTLA4+49 allele G was positively associated with AAD (P<0.0001, odds ratio (OR)=2.43, 95% confidence interval=1.54-3.86) also after correction for DRB1*03-DQA1*0501-DQB1*0201, DRB1*04-DQA1*0301-DQB1*0302, and sex. Meta-analysis of five studies revealed a significant association of CTLA4+49 allele G with AAD (P<0.0001) with an overall OR of 1.48 (1.28-1.71). CONCLUSIONS: The CTLA4+49 polymorphism is strongly associated with genetic risk for AAD, independently from the well-known association with HLA class II genes.
Authors: Min Kyung Shin; So Hee Im; Hae Jeong Park; Su Kang Kim; Sung Vin Yim; Joo-Ho Chung; Mu-Hyoung Lee Journal: Exp Ther Med Date: 2011-08-03 Impact factor: 2.447
Authors: Lidia Karabon; K Tupikowski; A Tomkiewicz; A Partyka; E Pawlak-Adamska; A Wojciechowski; A Kolodziej; J Dembowski; R Zdrojowy; I Frydecka Journal: Pathol Oncol Res Date: 2017-01-18 Impact factor: 3.201
Authors: Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871
Authors: A S B Wolff; A L Mitchell; H J Cordell; A Short; B Skinningsrud; W Ollier; K Badenhoop; G Meyer; A Falorni; O Kampe; D Undlien; S H S Pearce; E S Husebye Journal: Genes Immun Date: 2015-07-23 Impact factor: 2.676
Authors: Agnieszka Pazderska; Marta Fichna; Anna L Mitchell; Catherine M Napier; Earn Gan; Marek Ruchała; Mauro Santibanez-Koref; Simon H Pearce Journal: J Clin Endocrinol Metab Date: 2016-08-30 Impact factor: 5.958